BIG 1-12

Dit bericht delen

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)

Wissel inhoud

This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.

Pharmaceutical partners: Roche, Janssen Diagnostics

This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.

More To Explore


DIANER BIG 18-03 Share This Post A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients

Read More


SNAP BIG 2-12 Share This Post Schedules of nab-Paclitaxel: evaluation of different schedules of nab-paclitaxel for metastatic breast cancer What Schedules of Nab-Paclitaxel in Metastatic

Read More